What is VitaNova Life Sciences Corporation's earnings per share (EPS)?

VitaNova Life Sciences Corporation (YJGJD) reported diluted earnings per share of $0.03 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VitaNova Life Sciences Corporation (YJGJD) Financials

YJGJD

Trailing 12 months to January 31, 2026

Revenue $3.2M YoY not available

Net Income $745K YoY not available

EPS (Diluted) $0.03 FY2025 annual

Operating Cash Flow $865K +281.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jan 31, 2026 Reported Mar 16, 2026 Currency USD FYE April

Newest figures come from the 10-Q for Q3 FY2026, filed Mar 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YJGJD SEC filings page.

VitaNova Life Sciences Corporation (YJGJD) reported $3.2M in revenue over the twelve months to Jan 31, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI YJGJD FY2025 2026-08-30

Operating leverage is expanding rapidly, while cash conversion remains the less mature part of the business model.

Operating cash flow turned from -$376K in FY2024 to $193K in FY2025, but that remains well below FY2025 net income. With receivables at $1.0M, the business is recording profit faster than it is collecting cash.

After negative equity in FY2023, FY2025 equity reached $1.9M and debt-to-equity was 0.2x, indicating that recent growth has not required heavy balance-sheet leverage. A 5.9x current ratio adds substantial short-term asset coverage relative to current obligations.

Gross margin narrowed from 66.2% to 59.2%, yet operating margin expanded from 36.0% to 45.4%. FY2025 SG&A was only $158K, so expense growth was modest relative to the enlarged revenue base and explains the margin improvement.

Financial Health Signals

Financial health score not available

VitaNova Life Sciences Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

68.06

VitaNova Life Sciences Corporation scores 68.06, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($40.3M) relative to total liabilities ($380K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

VitaNova Life Sciences Corporation passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.23x

For every $1 of reported earnings, VitaNova Life Sciences Corporation generates $0.23 in operating cash flow ($193K OCF vs $851K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

268.16x

VitaNova Life Sciences Corporation earns $268.16 in operating income for every $1 of interest expense ($1.2M vs $5K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$710K

YoY+130.2%

QoQ+66.1%

VitaNova Life Sciences Corporation generated $710K in revenue in Q3 2026. This represents an increase of 130.2% from the same quarter a year earlier. Against the prior quarter it is up 66.1%.

Net Income

-$44K

YoY-160.8%

QoQ-223.9%

VitaNova Life Sciences Corporation reported -$44K in net income in Q3 2026. This represents a decrease of 160.8% from the same quarter a year earlier. Against the prior quarter it is down 223.9%.

EPS (Diluted)

-$0.01

VitaNova Life Sciences Corporation earned -$0.01 per diluted share (EPS) in Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$1.2M

YoY+188.5%

QoQ-7.2%

VitaNova Life Sciences Corporation held $1.2M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

25M

QoQ0.0%

5Y CAGR+33.6%

VitaNova Life Sciences Corporation had 25M shares outstanding in Q3 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

44.6%

YoY-16.8pp

QoQ-16.5pp

VitaNova Life Sciences Corporation's gross margin was 44.6% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 16.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 16.5 percentage points.

Operating Margin

6.6%

YoY-28.7pp

QoQ-16.6pp

VitaNova Life Sciences Corporation's operating margin was 6.6% in Q3 2026, reflecting core business profitability. This is down 28.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 16.6 percentage points.

Net Margin

-6.3%

YoY-29.9pp

QoQ-14.6pp

VitaNova Life Sciences Corporation's net profit margin was -6.3% in Q3 2026, showing the share of revenue converted to profit. This is down 29.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.6 percentage points.

Return on Equity

-2.4%

YoY-9.0pp

QoQ-4.3pp

VitaNova Life Sciences Corporation's ROE was -2.4% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.

Capital Allocation

None of these metrics is reported for Q3 2026.

YJGJD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

YJGJD quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$3.2M	$2.7M+366.5%	$571K+1401.8%	$38K-68.3%	$120K	$0	$0	$0	$0	$0
Cost of Revenue	$1.4M	$1.1M+462.9%	$193K	$0	N/A	N/A	N/A	$0	$0	$0
Gross Profit	$1.8M	$1.6M+317.2%	$378K+894.0%	$38K	N/A	N/A	N/A	$0	$0	$0
SG&A Expenses	$435K	$158K+82.3%	$87K+39.4%	$62K-53.3%	$133K+156.0%	$52K-28.0%	$72K+0.7%	$72K+47.6%	$49K+578.0%	$7K
Operating Income	$1.2M	$1.2M+487.6%	$206K+948.8%	-$24K-81.2%	-$13K+74.3%	-$52K+28.0%	-$72K-0.7%	-$72K-47.6%	-$49K	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$72K-47.6%	-$49K	N/A
Interest Expense	N/A	$5K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$449K	$354K+445.0%	$65K	$0	$0	$0	$0	$0	$0	N/A
Net Income	$745K	$851K+503.9%	$141K+681.4%	-$24K-117.3%	$140K+368.1%	-$52K+28.0%	-$72K+31.9%	-$106K-6556.2%	-$2K+77.8%	-$7K
EPS (Basic)	N/A	$0.03+200.0%	$0.01	$0.00-100.0%	$0.02+300.0%	-$0.01	N/A	N/A	N/A	N/A
EPS (Diluted)	—	$0.03	$0.01	$0.00-100.0%	$0.02+300.0%	-$0.01	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	25M	11M+81.3%	6M0.0%	6M0.0%	6M	N/A	N/A	5M+38.2%	4M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24
Revenue	$710K+130.2%	$427K+46.2%	$104K-4.2%	$2.0M	$308K+1081.3%	$292K	$108K	N/A
Cost of Revenue	$393K+230.5%	$166K+22.0%	$35K-0.5%	$796K	$119K	$136K	$35K	N/A
Gross Profit	$316K+67.1%	$261K+67.4%	$69K-6.0%	$1.2M	$189K+625.3%	$156K	$73K	N/A
SG&A Expenses	$220K+616.1%	$119K+197.8%	$66K+15.1%	$30K	$31K+52.2%	$40K+358.1%	$58K+137.4%	N/A
Operating Income	$47K-57.1%	$99K+58.4%	-$32K+28.6%	$1.1M	$109K+1730.4%	$63K+815.0%	-$45K-87.3%	N/A
Interest Expense	$0-100.0%	$0-100.0%	N/A	N/A	$813	$2K	N/A	N/A
Income Tax	$91K+158.2%	$63K+125.7%	$14K+41.5%	$280K	$35K	$28K	$10K	N/A
Net Income	-$44K-160.8%	$36K+9.7%	-$46K+16.1%	$800K	$73K+1126.9%	$33K+472.9%	-$55K-127.7%	N/A
EPS (Basic)	-$0.01-200.0%	$0.00	$0.00	N/A	$0.01	$0.00	$0.00	N/A
EPS (Diluted)	-$0.01	$0.00	$0.00	N/A	$0.01	$0.00	$0.00	N/A
Diluted Shares (Avg)	8M	25M0.0%	25M0.0%	N/A	8M+37.1%	25M	25M	N/A

Not reported in any period shown, so not listed: R&D Expenses, EBITDA.

YJGJD Balance Sheet

YJGJD quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$2.2M+86.7%	$1.2M+24.5%	$964K+3127.0%	$30K-29.4%	$42K	$0	$0-100.0%	$29K+1115.3%	$2K
Current Assets	$2.2M+86.7%	$1.2M	$0-100.0%	$30K-29.4%	$42K	$0	$0-100.0%	$10K	N/A
Cash & Equivalents	$1.0M+639.0%	$142K	$0-100.0%	$30K	$0	$0	$0-100.0%	$602+193.7%	$205
Inventory	$9K-95.7%	$213K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$380K+90.6%	$199K-81.0%	$1.0M+1570.1%	$63K-15.7%	$74K-44.4%	$134K+90.8%	$70K+2866.4%	$2K-60.8%	$6K
Current Liabilities	$380K+90.6%	$199K+138.9%	$83K+33.0%	$63K+95.4%	$32K-76.0%	$134K+90.8%	$70K	N/A	N/A
Non-Current Liabilities	$0	$0-100.0%	$964K	$0-100.0%	$42K	$0	$0	N/A	N/A
Total Equity	$1.9M+86.0%	$1.0M+1299.9%	-$83K-154.0%	-$33K-2.3%	-$32K+76.0%	-$134K-90.8%	-$70K-366.3%	$26K+816.4%	-$4K
Retained Earnings	$821K+2247.1%	-$38K+74.2%	-$148K-51.9%	-$98K-0.8%	-$97K+51.2%	-$199K-47.2%	-$135K	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24
Total Assets	$2.3M+75.0%	$2.3M+85.6%	$2.2M+86.7%	$2.3M+89.1%	$1.3M+37.0%	$1.3M	$1.2M	$1.2M+13567.0%
Current Assets	$2.3M+75.0%	$2.3M+85.6%	$2.2M+86.7%	$2.3M+89.1%	$1.3M+37.0%	$1.3M	$1.2M	$1.2M+13567.0%
Cash & Equivalents	$1.2M+188.5%	$1.3M+465.2%	$1.0M+639.0%	$783K+32.0%	$405K-49.9%	$223K	$142K	$593K+6694.6%
Inventory	$130K-30.1%	$11K-96.3%	$9K-95.7%	$44K-66.7%	$187K	$303K	$213K	$133K
Accounts Receivable	$1.0M+1759.5%	$883K+1429.7%	$1.0M	$1.3M	$54K	$58K	N/A	$0
Total Liabilities	$458K+115.2%	$438K+95.6%	$380K+90.6%	$348K+153.8%	$213K+127.4%	$224K+142.8%	$199K+138.9%	$137K+101.5%
Current Liabilities	$458K+115.2%	$438K+95.6%	$380K+90.6%	$348K+153.8%	$213K+127.4%	$224K+142.8%	$199K+138.9%	$137K+101.5%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$1.9M+67.3%	$1.9M+83.4%	$1.9M+86.0%	$1.9M+80.8%	$1.1M+27.3%	$1.0M+1222.2%	$1.0M+1299.9%	$1.1M+1883.2%
Retained Earnings	$813K+1106.6%	$857K+15382.8%	$821K+2247.1%	$868K+5017.7%	$67K+144.6%	-$6K+96.4%	-$38K+74.2%	$17K+113.7%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Long-Term Debt.

YJGJD Cash Flow Statement

YJGJD quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	$865K	$193K+151.3%	-$376K-1945.6%	-$18K-552.5%	$4K+109.6%	-$42K+21.1%	-$54K-9.1%	-$49K-428.4%	-$9K-43.1%	-$6K
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$40
Stock-Based Compensation	N/A	$2K+100.0%	$1K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	$0	$0	$0+100.0%	-$34K-1312.5%	-$2K
Financing Cash Flow	-$102K	-$3K-100.3%	$960K+23904.7%	$4K-79.0%	$19K-55.0%	$42K-21.1%	$54K+19.9%	$45K-5.8%	$47K+421.2%	$9K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24
Operating Cash Flow	-$90K-143.3%	$213K+2327.6%	$264K+152.3%	$479K+350.6%	$209K+238.7%	$9K+209.6%	-$504K-1827.6%	-$191K-8267.0%
Stock-Based Compensation	N/A	N/A	$0-100.0%	N/A	N/A	N/A	$750	N/A
Financing Cash Flow	$0+100.0%	$0-100.0%	$0-100.0%	-$102K-320.6%	-$27K-102.8%	$72K+806.0%	$53K+202.0%	-$24K

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

YJGJD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

YJGJD quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	59.2%-7.0pp	66.2%-33.8pp	100.0%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	45.4%+9.4pp	36.0%+99.8pp	-63.8%-52.6pp	-11.1%	N/A	N/A	N/A	N/A	N/A
Net Margin	32.0%+7.3pp	24.7%+88.4pp	-63.8%	116.4%	N/A	N/A	N/A	N/A	N/A
Return on Equity	45.7%+31.6pp	14.1%	N/A	N/A	N/A	N/A	N/A	-6.1%	N/A
Return on Assets	37.9%+26.2pp	11.7%+14.2pp	-2.5%-469.9pp	467.4%+590.5pp	-123.1%	N/A	N/A	-5.6%+298.3pp	-303.9%
Current Ratio	5.90-0.1x	6.02+6.0x	0.00-0.5x	0.48-0.8x	1.32+1.3x	0.000.0x	0.00	N/A	N/A
Debt-to-Equity	0.200.0x	0.20	N/A	N/A	N/A	N/A	N/A	0.09	N/A
Asset Turnover	1.19+0.7x	0.48+0.4x	0.04-4.0x	4.02+4.0x	0.00	N/A	N/A	0.000.0x	0.00

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'24
Gross Margin	44.6%-16.8pp	61.1%+7.7pp	66.2%-1.2pp	59.3%	61.4%-38.6pp	53.3%	67.5%	N/A
Operating Margin	6.6%-28.7pp	23.2%+1.8pp	-31.2%+10.7pp	55.4%	35.3%+12.5pp	21.4%	-41.9%	N/A
Net Margin	-6.3%-29.9pp	8.4%-2.8pp	-44.6%+6.3pp	41.0%	23.7%+0.9pp	11.2%	-50.9%	N/A
Return on Equity	-2.4%-9.0pp	1.9%-1.3pp	-2.5%+3.0pp	41.9%	6.6%+5.9pp	3.1%	-5.5%	N/A
Return on Assets	-1.9%-7.4pp	1.5%-1.1pp	-2.1%+2.5pp	35.5%	5.5%+4.9pp	2.6%	-4.6%	N/A
Current Ratio	5.05-1.2x	5.33-0.3x	5.90-0.1x	6.49-2.2x	6.21-4.1x	5.62+5.6x	6.02+6.0x	8.71+8.6x
Debt-to-Equity	0.25+0.1x	0.230.0x	0.200.0x	0.18+0.1x	0.19+0.1x	0.22	0.20	0.13
Asset Turnover	0.31+0.1x	0.180.0x	0.050.0x	0.87	0.23+0.2x	0.23	0.09	N/A

Not reported in any period shown, so not listed: FCF Margin.

Where VitaNova Life Sciences Corporation Ranks

Frequently Asked Questions

What is VitaNova Life Sciences Corporation's annual revenue?

VitaNova Life Sciences Corporation (YJGJD) reported $2.7M in total revenue for fiscal year 2025. This represents a 366.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is VitaNova Life Sciences Corporation's revenue growing?

VitaNova Life Sciences Corporation (YJGJD) revenue grew by 366.5% year-over-year, from $571K to $2.7M in fiscal year 2025.

Is VitaNova Life Sciences Corporation profitable?

Yes, VitaNova Life Sciences Corporation (YJGJD) reported a net income of $851K in fiscal year 2025, with a net profit margin of 32.0%.

What is VitaNova Life Sciences Corporation's gross margin?

VitaNova Life Sciences Corporation (YJGJD) had a gross margin of 59.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is VitaNova Life Sciences Corporation's operating margin?

VitaNova Life Sciences Corporation (YJGJD) had an operating margin of 45.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is VitaNova Life Sciences Corporation's net profit margin?

VitaNova Life Sciences Corporation (YJGJD) had a net profit margin of 32.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is VitaNova Life Sciences Corporation's return on equity (ROE)?

VitaNova Life Sciences Corporation (YJGJD) has a return on equity of 45.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is VitaNova Life Sciences Corporation's operating cash flow?

VitaNova Life Sciences Corporation (YJGJD) generated $193K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are VitaNova Life Sciences Corporation's total assets?

VitaNova Life Sciences Corporation (YJGJD) had $2.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does VitaNova Life Sciences Corporation have outstanding?

VitaNova Life Sciences Corporation (YJGJD) had 25M shares outstanding as of fiscal year 2025.

What is VitaNova Life Sciences Corporation's current ratio?

VitaNova Life Sciences Corporation (YJGJD) had a current ratio of 5.90 as of fiscal year 2025, which is generally considered healthy.

What is VitaNova Life Sciences Corporation's debt-to-equity ratio?

VitaNova Life Sciences Corporation (YJGJD) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is VitaNova Life Sciences Corporation's return on assets (ROA)?

VitaNova Life Sciences Corporation (YJGJD) had a return on assets of 37.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is VitaNova Life Sciences Corporation's Altman Z-Score?

VitaNova Life Sciences Corporation (YJGJD) has an Altman Z-Score of 68.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is VitaNova Life Sciences Corporation's Piotroski F-Score?

VitaNova Life Sciences Corporation (YJGJD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VitaNova Life Sciences Corporation's earnings high quality?

VitaNova Life Sciences Corporation (YJGJD) has an earnings quality ratio of 0.23x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can VitaNova Life Sciences Corporation cover its interest payments?

VitaNova Life Sciences Corporation (YJGJD) has an interest coverage ratio of 268.16x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.